We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Amplyx’s Fosmanogepix is being evaluated in ongoing phase 2 trials in both intravenous and oral formulations for treatment of life-threatening fungal infections. Read More
Deliveries of the J&J vaccine, which were recently paused as the European Medicines Agency investigated the risk of blood clots, are now resuming in Europe with a blood clot warning added to the product information. Read More
AstraZeneca (AZ) reportedly may not file for FDA Emergency Use Authorization (EUA) of its COVID-19 vaccine until mid-May as it needs more time to gather supporting data. Read More
Moderna said it plans to produce up to 3 billion doses of its messenger RNA-based COVID-19 vaccine globally in 2022, including booster shots against viral variants and pediatric vaccines. Read More
Pfizer has acquired San Diego, Calif.-based Amplyx Pharmaceuticals, broadening its portfolio of potential therapies for treating drug-resistant fungal infections. Read More
Merck has issued licenses to five Indian generic drugmakers to produce its COVID-19 antiviral molnupiravir in a move to expand global access to the drug. Read More
As work continues on remedying a host of concerning issues at Emergent BioSolutions’ Bayview, Md., facility, Health Canada has reported that the 1.5 million AstraZeneca (AZ) doses it received from the site were up to par for safety and quality. Read More